Figure 2. Response to TKI therapy is accompanied by a quick drop of plasma mutant DNA levels.

A subsequent time interval of low mutant EGFR levels indicates a phase of stable disease. For designations, please refer to legends of Fig. 1. OP: operation/tumour resection; MEK-Inhibit.: Selumetinib therapy.